We are grateful to the federal and state government agencies, foundations, universities, and companies who have funded our research on nanovaccines, nanotherapeutics, and nanoparticles. Here is a partial list of our recent sponsored projects, showing the project title, principal investigator (PI) and co-investigators (C0-Is), and project dates. Nanovaccine Institute researchers are marked in bold.
Current Awards
Department of Defense
“High-throughput metabolic spectral imaging to predict response to therapy in colorectal cancer”
R Bardhan, PI 09/20–08/22
“IL-1 based immunotherapy in head and neck squamous cell carcinoma”
A Burnett, PI; B Narasimhan, Co-I 05/20–02/24
“Multiplexed immunomarker screening to enable patient-tailored immunotherapies”
R Bardhan, PI 03/20–08/22
“Nanomedicine countermeasures to overcome antimicrobial resistance”
B Bellaire, PI; B Narasimhan, C0-I 12/18–12/21
National Institutes of Health
“Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection”
M Kohut & B Narasimhan, PIs; S Mallapragada, M Wannemuehler, D Verhoeven, D Nettleton, A Bronikowski, K Legge, Co-Is 02/21–01/26
“Developing multimodal multiplexed immunoPET-Raman probes to guide immunotherapies”
R Bardhan, PI 09/20–08/25
“PRADA: Portable Reusable Accurate Diagnostics with nanoAntennas for Multiplexed Biomarker Screening of Preterm Labor”
R Bardhan, PI 09/20–08/22
“Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancer”
S Rachagani, PI; S Mallapragada, Co-I 08/20–04/25
“Development of a mucosal, polyanhydride-based nanoparticle vaccine for use against RSV infection in the neonate”
J McGill & R Sacco, PIs; B Narasimhan, E Nicholson, Co-Is 09/19–07/23
–“Universal room temperature stable influenza nanovaccine”
B Narasimhan, PI; S Mallapragada, M Wannemuehler, D Verhoeven, M Kohut, B Sponseller, K Legge, K Carson, T Sullivan, Co-Is 01/19–12/23
“Nanovaccine platforms to combat pancreatic cancer”
B Narasimhan, PI; M Jain, A Salem, M Wannemuehler, Co-Is 09/17–08/22
“Nanovaccine-mediated immune protection against influenza virus”
K Legge, PI; T Waldschmidt, B Narasimhan, T Friedrich, Co-Is 06/17–05/22
U.S. Department of Agriculture
“Interleuken-17 as a target of therapeutic intervention for bovine respiratory disease”
J McGill, PI 08/19–07/22
“Optimizing an immunocastration vaccine ear implant to prevent pain associated with bovine castration”
J Coetzee, PI; D Jones, B Narasimhan, Co-Is 09/17–08/21
State Government
Iowa Regents Innovation Fund
“Development of flexible electronics fabrication platform”
M Uz, PI; S Mallapragada, Co-I 07/20–05/21
Companies
Merck & Company, Inc.
“Pulsatile release of multiple vaccine payloads from polyanhydride nanoparticles”
B Narasimhan, PI; M Wannemuehler, Co-I 02/19–05/21
Recently Completed Awards (ended within last three years)
National Institutes of Health
“Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity”
AG Kanthasamy, PI; A Kanthasamy, Co-I 04/16–03/21
“Modeling the Coupled Dynamics of Influenza Transmission and Vaccination Behavior”
R Vardavas, PI; A Parker, Co-I 02/16–01/21
“Determining the role of Interleukin-17 in the immune response to respiratory syncytial virus infection”
J McGill, PI 01/19–04/20
“Exosomes and Neuroinflammation in Parkinson’s Disease”
A Kanthasamy, PI; AG Kanthasamy, Co-I 02/15–11/19
“Enhanced Shelf-life Nanovaccine Formulation for Immunity to Biodefense Pathogens”
B Narasimhan, PI; M Wannemuehler, B Bellaire, J Hostetter, T Dubensky, Co-Is 09/14–08/19
“Role of Mitochondria-Targeted CYP2D6 in Chemical Toxicity”
AG Kanthasamy, Co-I 02/15–12/18
“Highly Simplified Model of a Mammalian Intestinal Community”
G Phillips, PI; J Hostetter, A Jergens, M Wannemuehler, Co-Is 12/12–11/17
“Function and Inhibition of Multidrug Efflux Systems in Campylobacter”
Q Zhang, PI; E Yu, Co-I 12/15–11/17
National Science Foundation
“On-chip studies of neuron cells under magnetic field stimulation”
Q Long, PI; D Jiles, I Schneider, Co-Is 06/16–05/20
“Planning Grant: Engineering Research Center for Aging-centric Engineering Technologies (AgETech)”
B Narasimhan, PI; R Jain, T Lockhart, J Margrett, C Hertzog, Co-Is 09/19–08/19
Department of Energy
“Nanozyme aptasensor diagnostic assay for detecting SARS-Cov-2”
R Bardhan, PI 07/20–11/20
U.S. Department of Agriculture
“Intracellular killing and biofilm destruction of MDR Salmonella by NK-Lysin encapsulated nanoparticles”
R Dassanayake, PI; B Narasimhan, Co-I 09/20–12/20
“Optimization and testing of a universal influenza vaccine for swine”
D Verhoeven, PI 06/17–05/20
“Next Generation Polyanhydride Nanovaccine Platform Technology for Poultry”
A Talaat, PI; B Narasimhan, Co-I 01/16–03/19
“Nanoparticle Delivery of Antibiotics for Disease Control in Cultured Shrimp”
L Bartholomay, PI; B Narasimhan and B Bellaire, Co-PIs 03/15–03/18
State Government
Iowa Economic Development Authority
“Development and manufacture of next-gen SARS-CoV-2 vaccine”
B Narasimhan, PI; M Wannemuehler, N Reuel, K Carson, K Legge, T Sullivan, Co-Is 10/20–12/20
Foundations, Associations
Howard Hughes Medical Institute
“Integrated Education and Research Program in Nanomedicine”
S Mallapragada, PI 01/18–12/20
PhRMA Foundation
“Develop Oral Vaccines with Miniguts”
Q Wang, PI 07/17–06/18
Crohns and Colitis Foundation
“Targeted Delivery of Intestinal Stem Cells to Treat Inflammatory Bowel Disease”
Q Wang, PI 07/15–06/18
Iowa Veterinary Medical Association
“Rapid Evaluation for Efficacy of Vaccines for Mycobacterium Avium SS Paratuberculosis in Cattle”
J Hostetter, PI; D Jones, Co-I 01/17–12/17
National Pork Board
“Efficacy of a Novel Intramammary Vaccine Delivery System for PEDV to Decrease Pre-weaning Mortality and Enhance Mechanisms of Immunity”
B Arruda, PI; P Arruda, D Jones, B Narasimhan, K Schwartz, J Zhang, Co-Is 12/16–12/17
Companies
AraVasc, Inc.
“Synthesis, characterization, and intracellular trafficking of pentablock copolymers”
S Mallapragada, PI 12/19–11/20
Imbed Biosciences, Inc.
“Nanomedicines to treat respiratory infections”
B Narasimhan, PI; D Verhoeven, M Wannemuehler, Co-Is 05/20–10/20
Triton Systems Inc.
“A Long-Term Anti-Malarial Drug-Releasing Implant”
B Narasimhan, PI 02/19–07/19
Merck & Company Inc.
“Investigation of a Candidate Universal Influenza Vaccine Targeting the HA Head”
D Verhoeven, PI; B Lee, B Sponseller, Co-Is 10/16–10/18
Merck & Company Inc.
“Investigation of Antibiotic-Resistant S. Pneumoniae Pathogenesis in a Unique Co-Infection Model”
D Verhoeven, PI; B Lee, M Ackermann, E Yu, Co-Is 11/16–10/18